R. Bugarini

发表

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

Jack Cuzick, Mitch Dowsett, Michael Baum, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Robert B Livingston, Lois Shepherd, James N Ingle, 2010, The Lancet. Oncology.

Phase I Evaluation of Intranasal Trivalent Inactivated Influenza Vaccine with Nontoxigenic Escherichia coli Enterotoxin and Novel Biovector as Mucosal Adjuvants, Using Adult Volunteers

R. Bugarini, J. Holmgren, K. Mills, 2006, Journal of Virology.

Maria Liguori, Maria Trojano, M. Trojano, 2002, Annals of neurology.

Low Frequency of Severe Hepatotoxicity and Association With HCV Coinfection in HIV‐Positive Patients Treated With HAART

M. Moroni, R. Bruno, A. Antinori, 2001, Journal of acquired immune deficiency syndromes.

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

M. Falchi, P. Monini, R. Bugarini, 2002, Nature Medicine.

Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant

A. Younes, S. Harrison, R. Bugarini, 2014, Leukemia & lymphoma.

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

R. Bugarini, M. Zambon, J. Katz, 2005, The Journal of infectious diseases.

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy.

R. Bugarini, D. Toneatto, D. Francisci, 2003, Vaccine.

Infection with human herpesvirus-8 and its correlation with hepatitis B virus and hepatitis C virus markers among rural populations in Cambodia.

M. Andreoni, R. Bugarini, G. Rezza, 2003, The American journal of tropical medicine and hygiene.

Kaposi's sarcoma‐associated herpesvirus serology in Europe and Uuganda: Multicentre study with multiple and novel assays

F. Goebel, F. Neipel, P. Monini, 2001, Journal of medical virology.

Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial.

R. Bugarini, E. Montomoli, I. Manini, 2009, Vaccine.

Highly Active Antiretroviral Therapy Restores CD4+ V&bgr; T-Cell Repertoire in Patients With Primary Acute HIV Infection But Not in Treatment-Naive HIV+ Patients With Severe Chronic Infection

G. D'offizi, C. Agrati, P. Narciso, 2004, Journal of acquired immune deficiency syndromes.

6573 POSTER Effect of Everolimus Treatment on Markers of Angiogenesis in Patients With Advanced Pancreatic Neuroendocrine Tumours (pNET) – Results From the Phase III RADIANT-3 Study

Z. Tsuchihashi, James C Yao, M. Pavel, 2011 .

Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.

J. Cuzick, J. Forbes, M. Dowsett, 2009 .

Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.

R. Bugarini, A. Podda, T. Tsai, 2009, The Journal of infectious diseases.

Associations of the correlates of protection and implication on the statistical power for demonstrating non-inferiority: application of a re-sampling method on a large phase III influenza vaccine clinical trial.

R. Bugarini, A. Podda, D. Casula, 2010, Vaccine.

Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients

C. Bellodi, C. Mussini, R. Bugarini, 2005, Immunogenetics.

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.

R. Rappuoli, R. Bugarini, D. Toneatto, 2006, Vaccine.

Persistently biased T-cell receptor repertoires in HIV-1-infected combination antiretroviral therapy-treated patients despite sustained suppression of viral replication.

G. Russo, R. Bugarini, A. Giovannetti, 2003, Journal of acquired immune deficiency syndromes.

GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer.

R. Gray, S. Martino, G. Sledge, 2009 .

Serum concentrations of fibroblast growth factor 2 are increased in HIV type 1-infected patients and inversely related to survival probability.

R. Bugarini, B. Ensoli, J. Bogner, 2001, AIDS research and human retroviruses.

A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.

R. Bugarini, A. Podda, A. Ambrozaitis, 2009, Vaccine.

Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study

C. Sabin, C. Mussini, G. Guaraldi, 2005, AIDS.

Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: the role of age.

C. Mussini, R. Bugarini, A. Cossarizza, 2001, The Journal of allergy and clinical immunology.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

A. d’Arminio Monforte, A. Antinori, A. De Luca, 2002, Archives of internal medicine.

Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome‐independent block of angiogenesis and matrix metalloproteinases

M. Falchi, P. Monini, R. Bugarini, 2011, International journal of cancer.

Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies

R. Bugarini, B. Suligoi, J. R. Fiore, 2003, AIDS.

Primary human herpesvirus 8 infection in immunocompetent children.

E. Nicastri, G. El Sawaf, M. Andreoni, 2002, JAMA.

Prevalence and Risk Factors for Human Herpesvirus 8 Infection in Northern Cameroon

P. Monini, P. Pezzotti, M. Andreoni, 2000, Sexually transmitted diseases.

Predilection sites of Trichinella spiralis larvae in naturally infected horses

R. Bugarini, E. Pozio, E. Goffredo, 1999, Journal of Helminthology.

Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene

R. Rappuoli, R. Bugarini, J. Donnelly, 2006, Clinical and Vaccine Immunology.

Antiretroviral therapy in HIV-infected individuals in clinical practice: Are the criteria for initiating and choosing the type of drug regimen based only on immunologic and virologic values?

G. Ippolito, P. Pezzotti, A. Monforte, 2004, European Journal of Epidemiology.

Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.

M. Broder, R. Bugarini, C. Chao, 2011, Journal of oncology practice.

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Silvana, R. Gray, E. Perez, 2011 .

Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011 .

Blood profiles, body fat and mood state in healthy subjects on different diets supplemented with Omega‐3 polyunsaturated fatty acids

R. Bugarini, B. Berra, F. Corradeschi, 2005, European journal of clinical investigation.

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

R. Gray, E. Perez, S. Martino, 2009, Clinical Cancer Research.

Prevalence and Risk Factors for Herpes Simplex Virus Type 2 Infection Among Adolescents and Adults in Northern Cameroon

R. Bugarini, G. Rezza, B. Suligoi, 2001, Sexually transmitted diseases.

Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system

C. Mussini, R. Bugarini, A. Cossarizza, 2006, AIDS.

Association of vorinostat with decrease in gene expression of proliferation-related genes in tumors from women with newly diagnosed breast cancer.

M. Fackler, E. Gabrielson, L. Jacobs, 2010 .

Biomarker analysis of pivotal phase II study of oral panobinostat (PAN) in relapsed/refractory Hodgkin lymphoma (HL) patients following autologous stem cell transplant (ASCT).

A. Younes, R. Bugarini, D. Ritchie, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.

D. Xuan, H. Burris, D. Hong, 2015 .

Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.

M. Moroni, R. Bruno, A. Antinori, 2001 .

Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100).

E. Winer, E. Perez, G. Hortobagyi, 2009 .

A novel mammalian cell-culture technique for consistent production of a well-tolerated and immunogenic trivalent subunit influenza vaccine.

R. Bugarini, A. Podda, A. Ambrozaitis, 2009, Vaccine.